Author:
Sandow J.,Jerabek-Sandow G.,Krauss B.
Reference41 articles.
1. Anik ST, McRae G, Nerenberg C, Worden A, Foreman J, Hwang JY, Kushinsky S, Jones RE, Vickery B (1984): Nasal absorption of nafarelin acetate, the decapeptide [D- Nal(2)6] LHRH, in rhesus monkeys I. Journal of Pharmaceutical Sciences 73, 684–885.
2. Barron JL, Millar RP, Di Searle (1982): Metabolic clearance and plasma half-disappearancetime of D-Trp6 and exogenous luteinizing hormone-releasing hormone. J Clin Endocrinol Metab, 54, 1169–1173.
3. Blom JHM, Hirdes WH, Schroeder FH, de Jong FH, Kwekkeboom DJ, van’t Veen AJ, Sandow J, Krauss B (1989): Pharmacokinetics and endocrine effects of the LHRH analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urological Research 17, 43–46.
4. Bourguignon JP, Hoyoux C, Reuter A, Franchimont P, Leinartz-Dourcy C, Vrindts-Gevaert Y (1979): Urinary excretion of immunoreactive luteinizing hormone-like material and gonadotropins at different stages of life. J Clin Endocrinol Metab, 48, 78.
5. Chan RL, Chaplin MD (1985): Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey. Drug Metab Dispos 13, 566–571.